Paolo Tarantino: The largest HER2-low sub-analysis of a RCT led by Guilherme Nader-Marta
Paolo Tarantino shared a recent article by Guilherme Nader-Marta et al. published in Breast Cancer Research. Read his post on X below:
Authors: Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Erica Mayer, Michael Gnant et al.
“The largest HER2-low sub-analysis of a RCT (PALLAS) just published in BCR, led by Guilherme Nader-Marta.
HER2-low expression was:
- not prognostic
- not predictive of palbo benefit
- highly heterogenous in prevalence across countries (range 16-75%; p < 0.001).”
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023